FULC (STOCKS)
Fulcrum Therapeutics, Inc. Common Stock
$7.730000
+0.180000 (+2.38%)
Prev close: $7.550000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Alexander C. Sapir
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $514.15M
- Employees
- 45
- P/E (TTM)
- -6.54
- P/B (TTM)
- 1.44
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
8
Buy
2
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.31 | $-0.32 | +0.0053 | +1.68% |
|
Sep 2025 (Q3)
|
$-0.31 | $-0.30 | -0.0104 | -3.47% |
|
Jun 2025 (Q2)
|
$-0.28 | $-0.30 | +0.0158 | +5.34% |
|
Mar 2025 (Q1)
|
$-0.28 | $-0.30 | +0.0199 | +6.64% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $84.77M |
| Research and Development | $52.74M |
| Other Operating Expenses | $32.03M |
| Operating Income/Loss | -$84.77M |
| Income/Loss From Continuing Operations After Tax | -$73.22M |
| Income/Loss From Continuing Operations Before Tax | -$73.22M |
| Net Income/Loss | -$73.22M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$73.22M |
| Net Income/Loss Available To Common Stockholders, Basic | -$73.22M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.18 |
| Diluted Earnings Per Share | -$1.18 |
| Basic Average Shares | 62,776,984 |
| Diluted Average Shares | 61,288,984 |
| Assets | $228.84M |
| Current Assets | $219.37M |
| Noncurrent Assets | $9.47M |
| Fixed Assets | $3.27M |
| Other Non-current Assets | $6.20M |
| Liabilities | $14.46M |
| Current Liabilities | $8.99M |
| Accounts Payable | $1.75M |
| Wages | $2.51M |
| Other Current Liabilities | $4.72M |
| Noncurrent Liabilities | $5.48M |
| Equity | $214.38M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $214.38M |
| Liabilities And Equity | $228.84M |
| Net Cash Flow From Operating Activities | -$64.91M |
| Net Cash Flow From Operating Activities, Continuing | -$64.91M |
| Net Cash Flow From Investing Activities | $19.77M |
| Net Cash Flow From Investing Activities, Continuing | $19.77M |
| Net Cash Flow From Financing Activities | $1.02M |
| Net Cash Flow From Financing Activities, Continuing | $1.02M |
| Net Cash Flow | -$44.13M |
| Net Cash Flow, Continuing | -$44.13M |
| Comprehensive Income/Loss | -$72.77M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$72.77M |
| Other Comprehensive Income/Loss | $448.00K |